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Background aims. The cost-effective production of human mesenchymal stromal cells (hMSCs) for off-the-shelf and patient
specific therapies will require an increasing focus on improving product yield and driving manufacturing consistency.
Methods. Bone marrowederived hMSCs (BM-hMSCs) from two donors were expanded for 36 days in monolayer with
medium supplemented with either fetal bovine serum (FBS) or PRIME-XV serum-free medium (SFM). Cells were assessed
throughout culture for proliferation, mean cell diameter, colony-forming potential, osteogenic potential, gene expression and
metabolites. Results. Expansion of BM-hMSCs in PRIME-XV SFM resulted in a significantly higher growth rate (P < 0.001)
and increased consistency between donors compared with FBS-based culture. FBS-based culture showed an inter-batch
production range of 0.9 and 5 days per dose compared with 0.5 and 0.6 days in SFM for each BM-hMSC donor line.
The consistency between donors was also improved by the use of PRIME-XV SFM, with a production range of 0.9 days
compared with 19.4 days in FBS-based culture. Mean cell diameter has also been demonstrated as a process metric for BM-
hMSC growth rate and senescence through a correlation (R2 ¼ 0.8705) across all conditions. PRIME-XV SFM has also
shown increased consistency in BM-hMSC characteristics such as per cell metabolite utilization, in vitro colony-forming
potential and osteogenic potential despite the higher number of population doublings. Conclusions. We have increased the
yield and consistency of BM-hMSC expansion between donors, demonstrating a level of control over the product, which has
the potential to increase the cost-effectiveness and reduce the risk in these manufacturing processes.
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The successful development of cell-based therapies
has the potential to address a number of currently
unmet clinical indications and to improve patient
care across the world. Growing interest in this
emerging field is evident by the large number of
recent acquisitions of cell-based therapy companies
by larger biopharmaceutical multinationals; for
example, FUJIFILM Holdings Corporation (TSE:
4901) recently acquired Cellular Dynamics Interna-
tional (NASDAQ: ICEL), a developer and manu-
facturer of induced pluripotent stem cells. However,
despite the progress, there are a number ofCorrespondence: Christopher J. Hewitt, MD, Aston Medical Research Institu
Birmingham B4 7ET, UK. E-mail: c.j.hewitt@aston.ac.uk
(Received 18 June 2015; accepted 3 August 2015)
ISSN 1465-3249 Copyright  2015, International Society for Cellular Therapy.
license (http://creativecommons.org/licenses/by/4.0/).
http://dx.doi.org/10.1016/j.jcyt.2015.08.002challenges that remain before cell-based therapies
can be incorporated into routine clinical practice and
their full potential realized.
Human mesenchymal stromal cells (hMSCs)
have demonstrated the potential to target a number
of these currently unmet conditions, with clinical
trials currently underway for indications such as
acute myocardial infarction, stroke and a host of in-
flammatory and immune disorders [1]. For the ma-
jority of these clinical indications, however, the
in vitro expansion of cells is required to deliver an
effective therapeutic dose. The intention of this
expansion step is to manufacture a sufficient numberte, School of Life and Health Sciences, Aston University, Aston Triangle,
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Improving yield and consistency of hMSC production 1525of cells to deliver therapeutic benefit without having a
detrimental impact on the quality of the cell at
decreasing production costs. Understanding and
defining the quality attributes of hMSC therapies will
be critical for their successful manufacture. This is
proving difficult, however, owing to their complex,
multifaceted and poorly understood in vivo mecha-
nism of action [2].
Cell-based therapies can be broadly divided into
two categories: patient-specific therapies (autolo-
gous) and off-the-shelf therapies (allogeneic).
Traditional biopharmaceutical manufacture is pre-
dominantly focused on universal treatments in which
multiple patients can be treated from a single batch.
The manufacture of patient-specific therapies, how-
ever, will require the careful consideration of regu-
latory challenges as well as the distribution and
delivery of a safe, effective and affordable cell-based
therapy [3]. This also introduces a range of addi-
tional challenges, not least of all how a cell therapy
manufacturing process can be developed to consis-
tently manufacture products from multiple donors
[4]. This will also be necessary for off-the-shelf
products because cellular senescence will limit their
expansion potential [5]. The key difference between
off-the-shelf and patient-specific therapies, however,
is that a donor selection process can be used for off-
the-shelf products to select donor cell lines that are
similar on the basis of expansion potential and
desired quality attributes.
A crucial factor determining the economic suc-
cess of off-the-shelf cell-based therapies in terms of
affordability probably will hinge on whether the pa-
tient receiving the hMSC therapy will require
immunosuppressive medication, increasing the
overall lifetime cost of the treatment, although most
clinical trials do not currently use them [6]. It has
been demonstrated previously [7,8] that the use of
serum during cell culture processes can lead to an
undesired increase in immune response in vivo, and
therefore the use of serum-free alternatives has the
potential to reduce the requirement for post-infusion
immunosuppressive medication. The development
of defined medium formulations for specific cell-
based therapies can also use this type of clinical
output as a basis for their development. These long-
term considerations for hMSC product manufacture
and delivery will be important to drive the develop-
ment of cost-effective and reimbursable therapies,
which has proved difficult to date.
Achieving the consistent manufacture of medici-
nal products is a key requirement for regulatory
approval and begins with assessing and reducing
process variation when possible [9]. Driving a
consistent process will demonstrate a state of control
over the product and provides a foundation forcomparability, whereby process changes during
clinical development can be validated and allows for
the product to be manufactured at multiple sites. A
key aspect of reducing variation in the process will be
reducing and eventually eliminating the use of fetal
bovine serum (FBS) from the cell culture medium
[10]. In addition to lot-to-lot variability, there are
further process constraints on the use of FBS such as
limited supply [11], spiraling cost, potential for
pathogen transmission, increased risk of recipient
immune reaction [12] and reduced scope for process
optimization. All of these considerations mean that
moving toward a serum-free process would be
beneficial in achieving scalable, tunable and consis-
tent hMSC manufacturing processes. In addition,
serum-free culture has been shown to be amenable to
scalable expansion technology such as micro-carriers
and stirred bioreactors, producing higher hMSC
yields per time unit than serum-based processes,
which will be important for driving down the pro-
duction cost of hMSC therapies [13,14] and is a key
focus for our group. That said, the current cost of
serum-free medium (SFM) for research is generally
higher than serum-based medium; however, as the
demand increases and higher yield processes can be
developed, these costs probably will be reduced over
time.
Considering the innate biological variability that
exists between donors and the importance of
ensuring a consistent manufacturing process, driving
this philosophy into process development at an early
stage is critical. Therefore, the aim of this study was
to demonstrate how the development of a serum-free
expansion process can drive increased consistency
and yield of hMSC manufacture between donors and
the benefits that this can bring as the process scale
increases.Methods
Monolayer culture
Human MSCs were isolated from bone marrow
aspirate purchased from Lonza obtained from two
healthy donors with informed consent: BM-hMSC 1
(lot: 071313B) and BM-hMSC 2 (lot: 071281D).
The local ethics committee approved the use of the
sample for research. Cells from passage 1 were cry-
opreserved at a density of 1e2  106 cells/mL in a
freeze medium containing 90% (vol/vol) FBS
(Hyclone) and 10% (vol/vol) dimethyl sulfoxide
(Sigma-Aldrich). For serum-free experiments,
hMSCs cryopreserved in serum underwent one
adaptation passage in SFM. Cells were grown in T-
flasks seeded at 5000 cells/cm2 at 37C in humidified
air containing 5% CO2. For serum-based culture,
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L glucose; Lonza) supplemented with 10% (vol/vol)
FBS (Hyclone) and 2 mmol/L UltraGlutamine
(Lonza) was exchanged every 3 days. For serum-free
culture, the growth surface of T-flasks was coated
with 0.4 mg/cm2 PRIME-XV human fibronectin
(Irvine Scientific) and cultured in PRIME-XV SFM
(Irvine Scientific) according to the manufacturer’s
instructions. On passage, the hMSCs were washed
with phosphate-buffered saline (PBS) without Caþ
or Mgþ and incubated for 4 min with trypsin (0.25
%)/ethylene diamine tetra-acetic acid (Lonza) for
serum-based culture or TrypLE Express (Invitrogen)
for serum-free culture. Dissociation reagents were
inactivated by the addition of appropriate growth
medium, and the cell suspension was centrifuged at
220g for 5 min. The supernatant was discarded and
the remaining pellet was re-suspended in an appro-
priate volume of culture medium.Analytical techniques
Analysis of glucose and lactate concentrations in the
spent medium was performed with the use of a
Cedex Bio-HT (Roche). Cell counting, mean cell
diameter and viability (by use of acridine orange
uptake and 40-6-diamidino-2-phenylindole exclu-
sion) was performed with the use of a Nucleo-
Counter NC-3000 automated mammalian cell
counter (Chemometec). The following parameters
were obtained:
Specific growth rate
Specific growth rate; m ¼ ln

CxðtÞ=Cxð0Þ

Dt
where m is the net specific growth rate (h1), Cx(t)
and Cx(0) are the cell numbers at the end and start of
the exponential growth phase, respectively, and t is
time (h).
Population doublings
Population doublings; Pd ¼ 1logð2Þ,log

CxðtÞ
Cxð0Þ

where Pd is the number of population doublings and
Cx(t) and Cx(0) are the cell numbers at the end and
start of the exponential growth phase, respectively.
Specific metabolite consumption/production rate
Specific metabolite flux;
qmet ¼

m
Cxð0Þ

,

CmetðtÞ  Cmetð0Þ
emt  1

where qmet is the net specific metabolite consumption
or production rate, m is the specific growth rate (h1),Cx(0) is the cell number at the end of the exponential
growth phase, Cmet(t) and Cmet(0) are the metabolite
concentrations at the end and start of the exponential
growth phase, respectively, and t is time (h).Quantitative osteogenesis assay
Osteogenesis was quantified by means of hMSC
collagen production with the use of the Sircol assay
(Biocolour) after osteogenic differentiation. Collagen
standards of acid-soluble collagen type I at 0, 0.1, 0.2
and 0.4 g/L were used to quantify the collagen pro-
duction. Bone marrowederived hMSCs (BM-
hMSCs) were seeded at 10,000 cells/cm2 in a well
plate with previously described cell culture medium;
after 3 days, culture growth medium was exchanged
to osteogenic medium (Irvine Scientific) and
cultured for 9 days with a medium exchange taking
place every 3 days. To quantify the collagen pro-
duction, cells were fixed with a solution of 5% acetic
acid (vol/vol) (Sigma) and 9% formaldehyde (vol/vol)
(Sigma) for 30 min at room temperature. The
monolayer was washed, and Sircol dye reagent
(Biocolour) was added to each well for 30 min,
removed and the cell monolayer was washed with
Acid-Salt Wash Reagent (Biocolour). Alkali Reagent
(Biocolour) was added to each well to release the
collagen-bound Sircol Dye Reagent, and the result-
ing solution along with the collagen standard was
quantified on a microplate reader (BMG Labtech) at
an absorbance of 555 nm.Colony-forming unit fibroblast efficiency
To assess the colony-forming unit fibroblast (CFU-f)
efficiency, BM-hMSCs were seeded in a T-flask at
10 cells/cm2 and cultured with a medium exchange
every 3 to 5 days. After 14 days of culture, cells were
washed with PBS and fixed in 4% formaldehyde (vol/
vol) (Sigma) for 30 min. Colonies were stained with
1% crystal violet (Sigma) in 100% methanol (wt/vol)
for 30 min. Stained colonies that were made up of
more than 25 cells were recorded as CFUs.RNA isolation
Cells were harvested for RNA isolation at the
beginning, middle and end of the expansion process.
Total RNA was collected with the use of TriFast
Reagent (Peqlab) according to the manufacturer’s
instructions. Potential genomic DNA contamination
was removed by digestion with DNase (Life Tech-
nologies) followed by reverse transcription at 50C
for 60 min with the use of Superscript III (Life
Technologies) and 250 ng Oligo(dT)18-primer (Life
Technologies).
Figure 1. Growth kinetics of the two BM-hMSC lines over 36 days of expansion. (A) Box-and-whisker plots demonstrate the increased
consistency and cumulative population doublings in SFM- compared with FBS-containing medium (P < 0.001); (B) specific growth rate of
hMSCs in FBS and SFM. Data are shown as mean  standard deviation (n ¼ 4).
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analysis
Quantitative real-time polymerase chain reaction
(PCR) was performed with the use of SYBR
GreenER quantitative PCR Supermix Universal
(Life Technologies); 1 SybrGreen I (Life Tech-
nologies) and 0.2 mmol/L primer each on the DNA
engine Opticon2 (Biorad) were additionally added,
through the use of these cycling conditions: primary
denaturation at 95C for 3 min, followed by 35 cy-
cles: 95C for 30 s, 60C for 30 s (36B4, p21,
CCL2)/55 C (Oct4) and 72C for 30 s followed by
fluorescence measurement. The following primers
for cell markers were used: CCL2 (recruits mono-
cytes, memory T cells and dendritic cells to the sites
of inflammation produced by either tissue injury or
infection, NM_002982.3) (Fw) 50-CCA AGG GCT
CGC TCA GCC AGA TGC-30, (Re) 50-CGG AGT
TTG GGT TTG CTT GTC CAGG-30; p21 (reg-
ulates the cell cycle and mediates cellular senescence,
NM_000389.4) (Fw) 50-CCG CCT GCC TCC
TCC CAA CT-30, (Re) 50-GAG GCC CGT GAG
CGA TGG AA-30, OCT4 (pluripotent marker
associated with self-renewal of undifferentiated cells,
NM_002701.4) (Fw) 50-GAG GAG TCC CAG
GAC ATC AA-30, (Re) 50-CAT CGG CCT GTG
TAT ATC CC-30 and vascular endothelial growth
factor (VEGF) (associated with vascularization
and growth of blood vessels, NM_001171623.1)
(Fw) 50-GGAAGGAGCCTCCCTCAGGGTTTC
G-30, (Re) 5¢-GCCGGAGTCTCGCCCTCCG
G -3¢. Serial dilutions of plasmid standards were
used as positive controls and for quantification.
Expression was normalized to the reference
gene 36B4 (ribosomal protein large P0 RPLP0,
NM_001002.3).Human MSC characterization
Immunophenotype analysis was performed by means
of multi-parameter flow cytometry before and afterthe hMSC expansion process with the use of a pre-
viously developed protocol [15]. Short-tandem
repeat analysis was completed by means of LGC
Standards (UK) under their cell line authentication
program. Morphology images were obtained with the
use of a light microscope (Nikon Eclipse TS-100).
The hMSC differentiation was induced through
the use of PRIME-XV differentiation SFM (Irvine
Scientific) according to the manufacturer’s in-
structions. After 21 days, the differentiation media
were removed and cells were rinsed with PBS fixed
with 4% (vol/vol) paraformaldehyde (PFA) at room
temperature. Adipocytes were stained with 1% (wt/vol)
oil red O (Sigma-Aldrich) in isopropanol at room
temperature and rinsed with distilled water. Osteo-
blasts were incubated with 2.5% (vol/vol) silver nitrate
(Sigma-Aldrich) under ultraviolet light (30-min expo-
sure), rinsed with distilled water and stained with fast
violet solution (Sigma-Aldrich) containing 4% (vol/vol)
napthol AS-MX phosphate alkaline (Sigma-Aldrich)
for 45 min at room temperature in the dark. Chon-
drocytes were stained with 1% (wt/vol) alcian blue
(Sigma-Aldrich) in 0.1 mol/L hydrochloric acid
(Sigma-Aldrich). After 30-min incubation, cells were
rinsed 3 times with 0.1 mol/L HCl. After staining,
differentiated cells were visualized under a light mi-
croscope (Nikon Eclipse TS-100).Statistical analysis
Results were deemed to be significant at a value of
P < 0.05 with the use of a two-tailed Student’s t-test.Results
Human MSC growth across multiple donor lines
Human MSCs are currently under clinical investi-
gation for the treatment of many diseases, with the
majority of these off-the-shelf therapies typically
requiring more than one billion cells per patient
Table I. Process time required to manufacture a theoretical batch
of 350M hMSCs, demonstrating variation in process time between
and within donor material that is reduced in the serum-free process.
Condition hMSC line
Per dose of 350M hMSCs
Process time
(days)
Inter-batch
range (days)
Inter-donor
range (days)
FBS BM-hMSC 1 23.5 0.9 19.4
BM-hMSC 2 39.5 5.0
SFM BM-hMSC 1 12.9 0.5 0.9
BM-hMSC 2 12.4 0.6
Assumptions: Starting population of 2M hMSCs expanded in the
T-flask process presented in this study.
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demand, a large cell expansion ratio will be required
to treat many patients from the same batch. Figure 1
shows the relative difference between a SFM,
PRIME-XV, and media supplemented with FBS in
terms of hMSC growth. It is clear that the SFM of-
fers a significantly higher proliferation rate over FBS
(P < 0.001), with a maximum specific growth rate of
0.471  0.009 per day compared with 0.244  0.018
per day during the 36-day expansion process. This
increased growth rate corresponds to a final median
cumulative population doubling level of 18.15 in the
SFM compared with 8.93 in FBS culture across the
two donors at the end of the 36-day expansion pro-
cess. This represents an increase of approximately
600 times the number of cells under the SFM culture
compared with FBS culture over this expansion
period, which dramatically increases the effective
product yield and potential scalability of the SFM
process to meet the needs of a large-scale, off-the-
shelf, cell-based therapy. Cells that have nutrient
deprivation typically spend longer in the G1 phase of
the cell cycle, resulting in slower proliferation [18].
The fact that the PRIME-XV medium supported a
more rapid cell growth therefore indicates that it may
provide a better nutritional balance or activates
growth regulation pathways, such as the PI(3)K
pathway, than the FBS-containing medium under
the medium exchange regimen used here.
One of the key driving factors for the overall pro-
duction cost of an hMSC therapy, as well as medium
cost, probably will be in the level of donor-to-donor
variability in play during the manufacturing process,
owing to increased process time and risk of batch
failure. The donor lines selected for this study had
previously demonstrated large differences in cellular
characteristics [4], which will particularly affect the
successful development of patient-specific hMSC
therapies. Figure 1A shows the inconsistency between
the growth characteristics of these hMSC lines, with a
range of 4.86 population doublings after the 36-day
FBS expansion process, demonstrating a diverging
process that occurs in FBS culture. In contrast to this
variance experienced in FBS culture and despite a
higher number of cumulative population doublings,
the SFM culture process had a corresponding range of
only 1.45 population doublings between these donors
and batch runs after 36 days in culture.
For the development of a patient-specific, cell-
based therapy, in which the inter-donor variability
must be accounted for during manufacture, this
reduction in product variance has a significant
benefit to the process. As discussed previously [4],
reducing the divergence in donor cell characteristics
will alleviate potential bottlenecks in the isolation,
expansion and delivery process, an importantconsideration for cell-based therapy process devel-
opment. In conjunction with this, a more consistent
expansion process will reduce the risk of product
batch failure, which for a patient-specific therapy will
mean that the patient will not be treated. Table I
shows the variability between the two BM-hMSC
lines for a hypothetical process requiring a batch
size of 350 million cells from a starting population of
two million cells [1]. This demonstrates the
increased consistency that can be achieved in the
SFM process between production batches and be-
tween donors, with a reduction in range from 19.4
days in the FBS process to 0.9 days in the serum-free
process. This also has advantages for off-the-shelf
therapies because it is possible to select material for
the expansion process by pre-screening hMSCs and
discarding those that do not display sufficient growth
kinetics. Under the SFM condition, both of the BM-
hMSC lines displayed similar process times between
donors and a reduced inter-donor range. This has
the potential to lead to reduced costs in the process
development phase because fewer donor lines will be
excluded (and therefore require testing) compared
with FBS culture and will be available for the pro-
duction process. The reduced process time to ach-
ieve this batch size in the serum-free condition will
also be advantageous for reducing the overall me-
dium costs because product batches can be manu-
factured in reduced time. Furthermore, an increase
in achievable cell number per batch will also increase
the material available for quality release testing,
which is an important consideration of patient-
specific therapies because each patient batch must
be independently tested before release. A study by
Deskins et al. [19] also demonstrated that three in-
dependent in vitro assays that were based on growth
rate, proliferative potential and ATP content were
able to predict in vivo performance, with hMSCs
performing above average in all three assays having
increased in vivo regenerative abilities.
Associated with the reduction in inter-donor
variability, further reductions in process input
Figure 2. Mean cell diameter of the two BM-hMSC lines over 36 days of expansion. (A) Reduced mean diameter of hMSCs cultured in
SFM- compared with FBS-based expansion; (B) correlation showing the relationship between mean cell diameter and specific growth rate of
the subsequent passage. Data are shown as mean  standard deviation (n ¼ 4).
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supply of raw materials. Considering the potential
issues surrounding the limited availability and batch-
to-batch variability of FBS [11], the development of
defined, SFM formulations will further drive con-
sistency into the manufacturing process. In this
model, culture medium can be manufactured to a
specific formulation, ensuring inter-batch consis-
tency and reducing overall costs by scaling up the
medium manufacturing process and benefitting from
increasing economies of scale. This is in contrast to a
manufacturing process that is based on FBS, in
which the cost of the culture medium will increase as
the process is scaled through clinical development
into commercial scale production. It should be
noted, however, that the development of a defined
medium formulation should be based on a rigorous
product understanding so that desired product at-
tributes are maximized and not affected by the
various medium components. These desired product
attributes could range from growth kinetics all the
way to functional attributes, which will depend on
the target clinical indication.Human MSC size during the expansion process
The cell diameter of the hMSCs throughout the
expansion process in both FBS and the SFM culture
has been measured to determine whether this attri-
bute remains consistent. It can be seen from Figure 2
that the hMSCs cultured in the SFM have a smaller
diameter throughout the expansion process
compared with FBS, which in volumetric terms
equates to around half the size (assuming complete
sphericity). The increase in cell diameter of BM-
hMSCs toward the end of the culture process is
associated with a reduction in growth rate (Figure 1)
and therefore stability in cell diameter throughout
culture will be important to maintain hMSC growth
kinetics. Figure 2B shows the relationship between
the mean cell diameter of the hMSC populationagainst the growth kinetics of the subsequent pas-
sage. This demonstrates that the smaller hMSCs
generally have higher growth kinetics, which has
been reported previously [20,21]. In addition to
growth, hMSC size is also linked to aging of hMSCs
and loss in differentiation potential [22,23] and
therefore increasing size can also be used as a sur-
rogate marker of hMSC senescence.
Importantly, the osmolality of the FBS-based and
PRIME-XV SFM is similar (0.31 and 0.29 Osmol/
kg, respectively), further indicating that the differ-
ence in cell size noted in Fiure 2A is not a simple
matter of a change in osmotic balance, although it
should be noted that the osmolality of the PRIME-
XV SFM is closer to human physiological condi-
tions [24]. Although the reasons for this relationship
are not clear, it can nonetheless provide a basis for
evaluating the stability of the hMSCs throughout
expansion and provide as an early indication that cell
growth kinetics may begin to reduce. The smaller cell
size in the SFM will also allow for higher number of
cells per area, an important attribute for adherent cell
expansion; however, the implications of this smaller
size on the functional properties must be assessed
during product pre-clinical and subsequent clinical
development.
The size of the hMSC also has the potential to
affect the post-transplant safety profile of the therapy,
and the impact of the process conditions on this
attribute should be considered in relation to the de-
livery method [25]. If the cell-based therapy is to be
delivered by intra-arterial infusion, there is a poten-
tial risk of micro-embolisms and decreased cerebral
blood flow, which must be mitigated by altering the
cell dose, infusion volume and velocity [26]. The size
of freshly isolated stem cells is w11 mm and can be
transported through capillaries, whereas expansion
has previously been shown to increase the size to
w20 mm, obstructing micro-vascular vessels after
infusion [27]. Considering that hMSCs cultured
under FBS reached a maximum cell diameter of 18.4
Figure 3. Box-and-whisker plots show per-cell metabolite flux of two BM-hMSC lines over 36 days of expansion. Shown are increased
variation of glucose consumption rate in FBS-containing culture (A) compared with serum-free culture (B) and increased variation of lactate
production rate in FBS-containing culture (C) compared with serum-free culture (D). Data are shown as n ¼ 4 for each BM-hMSC line.
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diameter of 15.5 mm, the smaller cell diameter ach-
ieved under SFM would offer advantages of reduced
risk of these complications. Cells of approximately 15
mm have previously been shown to carry reduced risk
of restricting cerebral blood flow, with larger cells
requiring a reduced dose and infusion rate [28]. At
the end of the expansion process, hMSCs cultured in
SFM showed a mean cell diameter of 14.73  0.6
mm (mean  range) compared with FBS culture,
with a cell diameter of 17.19  2.5 mm (mean 
range). The variability in cell diameter throughout
expansion in FBS-based medium could have further
implications for the delivery process in terms of cell
concentration and infusion rate, which probably
would have to be standardized during clinical
development. As well as an increase in hMSC pro-
ductivity, this demonstrates a further advantage of
SFM culture of hMSCs in terms of cell size consis-
tency, with a smaller cell diameter also maintained
throughout our scalable micro-carrier expansion
process [13].Human MSC net metabolite flux
The net metabolite flux of glucose and lactate has
been measured in FBS and SFM culture over the
expansion process to better understand the relative
consistency between the donor hMSCs with time in
culture. Figure 3 shows the per-cell flux of glucoseand lactate for FBS and SFM culture, with a range of
per-cell glucose flux of 24.29 and 8.81 pmol/cell per
day for FBS and SFM expansion, respectively. This
is concurrent with the relative flux of lactate per cell,
with a range of 22.47 and 2.11 pmol/cell per day for
FBS and SFM expansion, respectively. This
increased range in per-cell metabolite flux in FBS is
primarily due to increased variability at the end of the
expansion process and is associated with a reduction
in hMSC growth and increase in cellular senescence
that is not observed in the SFM, despite the higher
number of population doublings.
The net flux of metabolites has the potential to
form part of a panel of measurements for the pur-
poses of demonstrating comparability, whereby pro-
cess changes can be evaluated for their impact on
cellular characteristics. This understanding of the
cell during the expansion process will also be a
valuable tool during process scale-up to ensure that
the interaction between the cell and its environment
has not changed during technology transfer. This
highlights the importance of process analytical tech-
nology, which can be used to monitor and control
process and product attributes to ensure consistency
and quality in the final product. It can be seen in
Figure 3 that there is reduced per-cell consumption
of glucose and production of lactate in SFM culture,
which is likely to be a beneficial product attribute as
the process is scaled. This will be particularly
apparent once suspension-based expansion processes
Figure 4. Colony-forming efficiency and osteogenic potential of two BM-hMSC lines against number of population doublings throughout
the expansion process. (A) Colony-forming efficiency demonstrates increased consistency between BM-hMSC lines in SFM- compared with
FBS-based medium; (B) level of collagen deposition demonstrates maintenance in osteogenic potential of both BM-hMSC lines in SFM at a
high number of population doublings.
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106 cell/mL), in which the buildup of waste products
such as lactate has the potential to inhibit the
expansion process. Considering that the culture
medium is likely to contribute to a significant portion
of the cost of goods for hMSC production, product
attributes that reduce the usage of culture medium
will be increasingly beneficial at the large scale.Discussion
The increased consistency between donor hMSC
lines in terms of per-cell metabolite flux is a further
demonstration that the cells cultured in the SFM
conditions show reduced inter-donor variation, an
important consideration, given the large amount of
variation in cell-based therapy manufacture.
Although this has been demonstrated in the present
study for basic metabolites, there is scope to extend
this analysis to a larger panel of metabolic in-
termediates to provide a detailed understanding of
the impact of the process on the hMSC metabolic
characteristics during scale-up. The reason for this
increased consistency in the SFM has yet to be
explored in the literature; however, the combination
of hMSCs cultured on fibronectin with serum-free
growth medium has been previously shown to acti-
vate the platelet-derived growth factor receptor,
which is essential for cell migration [29]. Activation
of hMSCs in this way provides a potential mecha-
nism for the cell characteristics to converge because
the hMSCs are actively forced to utilize specific
cellular pathways, as opposed to serum-based cul-
ture, in which an abundance of various proteins are
available to the cells. This combination of a fibro-
nectin coating with growth medium supplemented
with platelet-derived growth factor has been used
previously to positively select for smaller, highly
proliferative cell populations from bone marrow,
termed multipotent adult progenitor cells [30]. Thispositive selection process could also be contributing
to the increase in consistency measured in several
different characteristics under serum-free conditions,
as discussed further below.Ensuring consistency in hMSC characteristics
There is currently much discussion about the true
identity and desired characteristics of hMSCs for
clinical applications and how they elicit their thera-
peutic mechanism of action [31]. Despite this, some
hints come from a graft-versus-host disease study
showing that just a few passages can make a signifi-
cant difference. Human MSCs from passages 1e2
compared with passages 3e4 showed a decrease in
patient survival and response, whereas no in vitro
differences were found [32]. Despite this uncertainty
in the application of hMSCs, there is still a need to
rigorously characterize the cellular product during
the development of an expansion process to ensure
the process itself is not having a detrimental impact
on the product characteristics while yield is
increased. It is important that assay development
takes place in parallel with clinical development so
that the prediction of clinical effect for a specific
target indication can be correlated to process mea-
surements in vitro.
As hMSC expansion processes move through the
development phase, there is an increasing need to
assess the characteristics of the product in relation to
the number of population doublings the cells have
undergone and is favorable under the current regu-
latory guidelines. This has the benefit of normalizing
cell expansion data because passage number does not
take into account the seeding density of the cells or
the relative expansion level of the product in each
condition. The use of population-doubling level
versus cellular characteristic in this way allows for a
fair comparison between conditions and is far more
amenable to comparisons with scale-up technology
Figure 5. Quantitative real-time PCR analysis shows RNA expression of four hMSC genes for the two BM-hMSC lines in FBS (blue) and
SFM (green) expansion. Shown are maintained expression of CCL2 (A), P21 (B) and Oct4 (C) and a reduction in expression of VEGF-A
(D) in SFM culture. Complementary DNA is normalized to housekeeping gene 36B4. Solid line indicates BM-hMSC 1; dashed line, BM-
hMSC 2.
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not readily apply. Figure 4 shows the colony-forming
potential and osteogenic potential of the hMSC
donor lines under FBS and SFM culture against the
number of population doublings. This demonstrates
that both product attributes decrease through the
expansion process as the number of population
doublings increases, which hints at the challenges
that exist when developing large-scale manufacturing
processes, which are likely to require lot sizes in
excess of a trillion cells [33].
Despite this, hMSCs cultured in SFM retained a
similar level of colony-forming potential at a high
number of population doublings, and, importantly,
the consistency between the two hMSC donor lines
was far greater than in FBS. Our data therefore
suggest that the SFM condition used, PRIME-XV,
in conjunction with growth on fibronectin, is able
to support the generation of a more homogenous cell
population in terms of colony-forming potential as
well as cell size and growth rate, possibly through a
positive selection process or the maintenance of
asymmetric division. Indeed, an increased presence
of CFU-F in an MSC population has previously been
noted when an optimized defined medium formula-
tion is used as compared with DMEM/FBS [34].
Furthermore, Wagner et al. [35], who compared two
serum-containing media, also noted that one was
able to support a more homogenous morphology
than the other. This maintenance of consistencybetween donors will be important for both patient-
specific and off-the-shelf therapies and will reduce
the likelihood of product batch failure during quality
testing. This will result in a reduced cost at the large
scale because the capital invested per batch will be
high, but, more importantly, for patient-specific
therapies, a batch failure would result in a patient
going without treatment, which would be highly
undesirable.
It is also important that the hMSCs retain the
expression of key genes throughout the expansion
process because they are likely to play a key role in
the product performing its function in vivo. Figure 5
shows the RNA expression of the donor hMSC lines
in FBS and the SFM culture against population-
doubling level. It is clear that despite the increased
population-doubling level, hMSCs cultured under
SFM conditions retained the expression of all four
genes analyzed, indicating that the positive selection
we believe is occurring to generate the more ho-
mogenous population is not affecting the expression
of key genes. CCL2 has been implemented in the
recruitment of T-cells, monocytes and dendritic cells
to the sites of inflammation [36] and is therefore an
important gene to maintain for clinical indications
that require a level of immune modulation.
Figure 5B shows that the relative expression of P21, a
gene relating to cellular aging and senescence, has
not unduly increased throughout the expansion
process in SFM or FBS culture. Oct4 is a marker of
Figure 6. Phase-contrast images of the two BM-hMSC lines show the increased consistency in morphology between the cell lines under
SFM expansion compared with FBS.
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cells, but has previously demonstrated expression in
hMSCs [37]. Maintenance of Oct4 under SFM
expansion demonstrates the continued ability of the
cells to self-proliferate at high population-doubling
levels and will be important for the clinical applica-
tion of cell-based products that undergo cellular
differentiation. VEGF has been shown to be a highly
important gene in the promotion of angiogenesis by
hMSCs [38], which will be important in a number of
clinical indications, particularly for cardiac repair
[39], a key target for a number of hMSC-based
therapies. Despite a higher relative expression of
VEGF in hMSCs cultured in SFM, there is a
decrease in the expression of VEGF as the number of
population doublings increases, which should be
further investigated if the hMSC product requires a
high level of cumulative population doublings and is
to be used for clinical indications requiring
angiogenesis.
Figure 6 shows the difference in hMSC
morphology between donor lines in FBS-based cul-
ture that is reduced in SFM culture, with smaller
spindle-shaped cells. This increased consistency be-
tween donors in cellular morphology observed in
SFM has benefits for the development of
manufacturing processes that are based on a fixed
surface area. This will be particularly apparent for
patient-specific therapies, in which the number ofobtainable cells per square centimeter will determine
the final cell yield of the product batch. Considering
that manufacturing processes for these cell-based
therapies probably will have a minimum number of
cells per dose, this reduced variation under SFM will
greatly reduce the risk of product batch failure,
increasing the cost-efficiency of the process. As well
as morphology, the hMSCs have demonstrated the
desired immunophenotype and tri-lineage differen-
tiation potential in FBS and SFM culture throughout
the entire expansion process (Supplementary
Figure 1). Additionally, hMSCs in both conditions
have demonstrated the correct genotype profile at the
end of the expansion process, as determined by
means of short-tandem repeat analysis for each
donor cell line (Supplementary Figure 2).Conclusions
The development of consistent manufacturing
processes remains a key challenge that must be
overcome to ensure the successful translation of
cell-based therapies. SFM has the potential to reduce
the variability of input material to these processes,
which will allow for increased control over process
consistency. By developing a serum-free process, we
have increased the yield and consistency of hMSC
expansion between donors, which offers large
1534 T. R.J. Heathman et al.advantages in the development of both off-the-shelf
and patient-specific cell-based therapies. The con-
vergence of hMSC characteristics throughout an
expansion process demonstrates a level of control
over the product manufacture, which has the po-
tential to increase the cost-effectiveness and reduce
the risk in these processes.Acknowledgments
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